Sodium (3-amino-1-hydroxy-1-phosphonopropyl)phosphonate xhydrate, 95.0%, 1g

4-Fluoro-2-methylanisole, 95.0%, 5g

1-(2-Chlorophenyl)cyclobutan-1-amine hydrochloride, 95.0%, 1g

Fmoc-Threoninol, 95%, 25g

2-Bromo-4-(difluoromethoxy)aniline, 97.0%, 250mg

(S)-Methyl 6-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-aminohexanoate hydrochloride, 97%, 25g

4-Amino-2,6-dihyroxypyrimidine, 98.0%, 250g

5-(4-METHYLPYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE, 90.0%, 250mg

Octan-2-yl (2,4-Dichlorophenoxy)acetate>96.0%(GC)1g

Homoveratrylamine>98.0%(GC)(T)25g

1-(4-(Trifluoromethyl)phenyl)cyclobutanecarboxylic acid, 95.0%, 5g

Microliter syringe GASTIGHT® series 1000, 5.0 ml, 1005 TLL, 1 piece

1-Ethyl-1H-pyrazole-4-carbaldehyde, 95.0%, 250mg